Antibiotice SA 2015 Annual Report with Sustainability Disclosures
The report highlights the achievements of Antibiotice in 2015, marking its 60th anniversary. The company ranked fourth among generic drug manufacturers in Romania and first globally in Nystatin active substance production. Financially, sales revenues reached RON 330 million, a 3% increase from 2014, despite domestic market challenges. Antibiotice expanded its international presence, tripling Nystatin exports to the US. The company also advanced its sustainability efforts through selective waste collection, energy efficiency measures, and community support via the 'Antibiotice - Science and Soul' Foundation.
Company: Antibiotice SA
Sector: Manufacturing
Country: Romania
Year: 2015
Type: Annual Report with Sustainability Disclosures
Pages: 95
Back to company
Antibiotice SA
Annual Report
The report highlights the achievements of Antibiotice in 2015, marking its 60th anniversary. The company ranked fourth among generic drug manufacturers in Romania and first globally in Nystatin active substance production. Financially, sales revenues reached RON 330 million, a 3% increase from 2014, despite domestic market challenges. Antibiotice expanded its international presence, tripling Nystatin exports to the US. The company also advanced its sustainability efforts through selective waste collection, energy efficiency measures, and community support via the 'Antibiotice - Science and Soul' Foundation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees